CA Patent

CA2793313A1 — Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders

Assigned to Ogeda SA · Expires 2011-10-06 · 15y expired

What this patent protects

The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

USPTO Abstract

The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

Drugs covered by this patent

Patent Metadata

Patent number
CA2793313A1
Jurisdiction
CA
Classification
—
Expires
2011-10-06
Drug substance claim
No
Drug product claim
No
Assignee
Ogeda SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.